Terms: = Lymphoma AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
814 results:
1. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
2. Phase II study of novel orally pi3kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Wang H; Feng J; Liu Y; Qian Z; Gao D; Ran X; Zhou H; Liu L; Wang B; Fang M; Zhou H; Huang Z; Tao S; Chen Z; Su L; Su H; Yang Y; Xie X; Wu H; Sun P; Hu G; Liang A; Li Z
Signal Transduct Target Ther; 2024 Apr; 9(1):99. PubMed ID: 38627366
[TBL] [Abstract] [Full Text] [Related]
3. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
4. Duvelisib: A comprehensive profile.
Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
[TBL] [Abstract] [Full Text] [Related]
5. [Effect of Chlorambucil Combined with Ibrutinib on Mantle Cell lymphoma Cell Line Jeko-1 and Its Related Mechanism].
Cai NN; Liu WY; Liu ZQ; Gong JH; Lin YL; Wang ZC; Huang YQ; Guo JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):132-137. PubMed ID: 38387911
[TBL] [Abstract] [Full Text] [Related]
6. A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome.
Messana VG; Fascì A; Vitale N; Micillo M; Rovere M; Pesce NA; Martines C; Efremov DG; Vaisitti T; Deaglio S
Blood Adv; 2024 Apr; 8(8):1920-1933. PubMed ID: 38359376
[TBL] [Abstract] [Full Text] [Related]
7. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
[TBL] [Abstract] [Full Text] [Related]
8. treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
Zygmunciak P; Robak T; Puła B
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338868
[TBL] [Abstract] [Full Text] [Related]
9. In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of pi3k/AKT/mTOR pathway.
Diab SE; Tayea NA; Elwakil BH; Elshewemi SS; Gad AAEM; Abdulmalek SA; Ghareeb DA; Olama ZA
Sci Rep; 2024 Jan; 14(1):2433. PubMed ID: 38286826
[TBL] [Abstract] [Full Text] [Related]
10. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
[TBL] [Abstract] [Full Text] [Related]
11. Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.
Feng X; Yang L; Liu X; Liu M; Liu L; Liu J; Luo J
Med Oncol; 2024 Jan; 41(2):60. PubMed ID: 38252204
[TBL] [Abstract] [Full Text] [Related]
12. Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Morcos PN; Moss J; Veasy J; Hiemeyer F; Childs BH; Garmann D
Clin Pharmacol Ther; 2024 May; 115(5):1092-1104. PubMed ID: 38226495
[TBL] [Abstract] [Full Text] [Related]
13. ATF5 promotes malignant T cell survival through the pi3k/AKT/mTOR pathway in cutaneous T cell lymphoma.
Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
[TBL] [Abstract] [Full Text] [Related]
14. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract] [Full Text] [Related]
15. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
[TBL] [Abstract] [Full Text] [Related]
16. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
17. The role of α7-nAChR-mediated pi3k/AKT pathway in lung cancer induced by nicotine.
He Z; Xu Y; Rao Z; Zhang Z; Zhou J; Zhou T; Wang H
Sci Total Environ; 2024 Feb; 912():169604. PubMed ID: 38157907
[TBL] [Abstract] [Full Text] [Related]
18. ERBB4-Mediated Signaling Is a Mediator of Resistance to pi3k and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
19. High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::ALK rearrangement: Changes in genetic status using genetic testing during treatment with an ALK inhibitor.
Watanabe T; Honma Y; Yonemori K; Sunami K; Yoshimoto S; Mori T
Head Neck; 2024 Mar; 46(3):E26-E31. PubMed ID: 38018800
[TBL] [Abstract] [Full Text] [Related]
20. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the pi3k inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract] [Full Text] [Related]
[Next]
